Background/Aims: HOTTIP is a critical modulator in human diseases including liver cancer, but its role and molecular biological mechanisms in liver fibrosis are still unclear. Methods: The expression profile of HOTTIP during the progression of liver fibrosis was detected in human liver samples and in CCl 4 -treated mice using qRT-PCR. The expressing sh-HOTTIP adenoviral vector was used to reduce HOTTIP levels in vivo. Dual-Luciferase Reporter Assay was performed to validate the interaction between miR-148a and HOTTIP, TGFBR1, or TGFBR2. Results: HOTTIP expressions in fibrotic liver samples and cirrhotic liver samples were significantly upregulated compared with healthy liver controls, and cirrhotic samples exhibited the highest levels of HOTTIP. Moreover, HOTTIP expressions were substantially induced in the liver tissues and hepatic stellate cells (HSC) of CCl 4 -treated mice. Ad-shHOTTIP delivery could alleviate CCl 4 -induced liver fibrosis in mice. Down-regulation of HOTTIP inhibited the viability and activation of HSCs in vitro, and HOTTIP negatively regulated miR-148a expression in HSCs. miR-148a had a negative effect on HSC activation by targeting TGFBR1 and TGFBR2. Conclusion: HOTTIP is involved in the progression of liver fibrosis by promoting HSC activation. The high level of HOTTIP downregulates miR-148a, thus to increase the level of TGFBR1 and TGFBR2 and contribute to liver fibrosis.
vertebra, and liver tissues were removed for use in the study.
For delivery of the expressing sh-HOTTIP adenoviral vector, Ad-shHOTTIP, the CCl 4 -treated mice received Ad-shHOTTIP (1×10 9 pfu/100μL) or its control (1×10 9 pfu/100μL) by intravenous injection once every 2 weeks for 6 weeks (three times). After 6 weeks, the mice were killed by breaking cervical vertebra, and the liver tissues were used for analysis. In this part of the study, C57BL/6J mice were randomly divided into four groups (n=12 per group): control, CCl 4 group, CCl 4 +Ad-shCtrl group, and CCl 4 +Ad-shHOTTIP group. The mouse experimental protocols were performed following "The Guide for the Care and Use of Laboratory Animals" and approved by the Ethics Committee of The First Affiliated Hospital of Zhengzhou University.
Culture of primary HSCs and hepatocytes
The primary HSCs were isolated according to the detailed protocol in [17] [18] [19] and then cultured in DMEM (HyClone, South Logan, UT, USA) containing 10% fetal bovine serum (FBS, Gibco, Waltham, MA, USA), 1% penicillin-streptomycin (HyClone, South Logan, UT, USA) at 37°C with 5% CO 2 . The primary hepatocytes were isolated as described in [20] and were cultured in Williams' medium E (Biochrom, Cambridge, UK) supplemented with 10% FBS (Gibco, Waltham, MA, USA), 1% penicillin-streptomycin (HyClone, South Logan, UT, USA), at 37°C with 5% CO 2 .
Quantitative real-time PCR (qRT-PCR) analysis
In this study, the expressions of HOTTIP, miR-148a, α-SMA, Col-1, TGFBR1, TGFBR2, Smad2, and Smad3 mRNA were determined in liver tissues or cells through the use of qRT-PCR analysis. Total RNA was extracted from liver tissues or cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The concentration of total RNA was quantified on a NanoDrop 2000C spectrophotometer (Thermo Scientific, Waltham, MA, USA). The total RNA (equal amounts of each sample) was reverse transcribed into cDNA using PrimeScript cDNA Synthesis Kit (TaKaRa Biotechnology, Kusatsu, Japan). The qRT-PCRs of HOTTIP, α-SMA, Col-1, TGFBR1, TGFBR2, Smad2 and Smad3 were performed using SYBR Green Real-Time PCR Master Mixes (Applied Biosystems, Foster City, CA, USA) with specific primers on an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The primers used were as follows: HOTTIP, (forward) 5'-CACACTCACATTCGCACACT-3' and (reverse) 5'-TCCAGAACTAAGCCAGCCATA-3'; α-SMA, (forward) 5'-CTGACAGAGGCACCACTGAA-3' and (reverse) 5'-CATCTCCAGAGTCCAGCACA-3'; Col-1, (forward) 5'-GATTGAGAACATCCGCAGC-3' and (reverse) 5'-CATCTTGAGGTCACGGCAT-3'; TGFBR1, (forward) 5'-AAACTTGCTCTGTCCACGG-3' and (reverse) 5'-AATGGCTGGCTTTCCTTG-3'; TGFBR2, (forward) 5'-GTAATAGGACTGCCCATCCAC-3' and (reverse) 5'-GATTTCTGGTTGTCACAGGTG-3'; Smad2, (forward) 5'-AGCAGAATACCGAAGGCAG-3' and (reverse) 5'-TTTGTCCAACCACTGTAGAGGT-3'; Smad3, (forward) 5'-GCTGCTCTCCAATGTCAACAG-3' and (reverse) 5'-TCTTCCGATGTGTCTCCGT-3'. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the internal control. For miR-148a expression analysis, total RNA extracted from liver tissues and cells was reverse transcribed into cDNA using the Advanced miRNA cDNA Synthesis Kit (Applied Biosystems, Foster City, CA, USA) and the qRT-PCR was performed using SYBR Green master mix (CoWin Biotech, Beijing, China) according to the manufacturer's instructions. U6 was used as the internal control for miR-148a.
Western blot analysis
The protein expressions of α-SMA, Col-1, TGFBR1, TGFBR2, Smad2 and Smad3 were determined using Western blot analysis. Total protein was extracted from liver tissues or cells using lysis buffer (Beyotime Biotechnology, Haimen, China) according to the manufacturer's instructions. The concentration of total protein was quantified using a BCA kit (Beyotime Biotechnology, Haimen, China) according to the manufacturer's instructions. The total protein (20μg per sample) was separated by SDS-PAGE and transferred onto PVDF membranes (Millipore, Burlington, MA, USA), and the PVDF membranes were blocked with 5% skimmed milk for 1h. The proteins on PVDF membranes were then incubated with the primary antibodies of anti-α-SMA (1:2000, Abcam, Cambridge, UK), anti-Col-1 (1:1000, Novus Biologicals), anti-TGFBR1 (1:2000, Abcam, Cambridge, UK), anti-TGFBR2 (1:2000, Abcam, Cambridge, UK), anti-Smad2 (1:1000, Novus Biologicals, Littleton, CO, USA), anti-Smad3 (1:1000, Novus Biologicals, Littleton, CO, USA) and β-actin (1:2000, ProteinTech Group, Inc., Chicago, IL, USA) overnight at 4°C. The proteins on were then incubated with the appropriate HRP-conjugated secondary antibodies. The bands were visualized using ECL Substrate (Thermo Scientific, Waltham, MA, USA) and quantified using Quantity One imaging software 
Analysis of hydroxyproline (HYP) content
The hydroxyproline (HYP) content of mouse liver tissues was measured using the commercial HYP colorimetric assay kit (BioVision, Milpitas, CA, USA) according to the manufacturer's instructions. Briefly, the liver tissue homogenates were hydrolyzed overnight and then centrifugated to collect the supernatant. After being dried under vacuum, the extract was used for analysis of HYP content.
Cell transfection
In this study, the transfections of si-HOTTIP (Shanghai GenePharma Co., Ltd., Shanghai, China), pcDNA-HOTTIP (Shanghai GenePharma Co., Ltd., Shanghai, China), miR-148a mimic and inhibitor (RiboBio, Guangzhou, China) were used for modulating the expression of HOTTIP and miR-148a in HSCs in vitro. The HSCs were cultured at a concentration of 2.0×10 5 cells/ml overnight and then transfected with si-HOTTIP (30nM), pcDNA-HOTTIP (30nM), miR-148a mimic (20nM), miR-148a inhibitor (20nM), or their control using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
MTT assays
Cell viability was determined using MTT assays. The HSCs (2.0×10 3 cells/well) were cultured in 96-well plates overnight, and then transfected with si-HOTTIP (30nM) or its control using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. After 24h of transfection, the cells in each well were incubated with MTT solution (20μL, 5mg/mL) for 4h at 37°C. After removal of the medium, DMSO (150μL) was added into each well for 10min. The absorbance of each well was detected at 490 nm on a microplate spectrophotometer (Molecular Devices, San Jose, CA, USA).
Luciferase activity assays
Dual-Luciferase pmirGLO plasmid was purchased from Promega (Madison, WI, USA). The HOTTIP luciferase reporter vectors containing miR-148a binding site (pmirGLO-HOTTIP) or mutated site (pmirGLO-HOTTIP-MU) were constructed by Shanghai GenePharma Co., Ltd. HEK293T cells were cultured in 24-well plates and transfected with miR-148a mimic/inhibitor and pmirGLO plasmid using Lipofectamine 2000 and X-tremeGENE HP (Roche Applied Science, Penzberg, Germany), respectively. After 48h of transfection, the luciferase activity was assessed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer's instructions. Dual-Luciferase Reporter Assay was also performed as described above to validate the direct binding between miR-148a and TGFBR1/TGFBR2. Three independent experiments were carried out.
Statistical analysis
All data from three independent experiments were expressed as mean values±standard deviation (SD). The comparison between two groups was conducted using Student's test on GraphPad 6.0 software (Prism, La Jolla, CA, USA), and P<0.05 was considered statistically significant.
Results

HOTTIP was upregulated during the progression of liver fibrosis
The liver samples from patients with liver fibrosis in chronic hepatitis B (Fibrotic samples, n=30), patients with liver cirrhosis (Cirrhotic samples, n=30), and healthy controls (n=30) were collected and used for analysis of the relative expression of HOTTIP during the progression of liver fibrosis. HOTTIP expressions in fibrotic liver samples and cirrhotic liver samples were significantly upregulated in comparison to the healthy liver controls, and cirrhotic samples exhibited the highest level of HOTTIP (Fig. 1A) . Moreover, HOTTIP expression was substantially induced in the mouse liver tissues (n=12) by intraperitoneal injection of CCl 4 (Fig. 1B) , a typical method for inducing liver fibrosis. We further analyzed the expressions of HOTTIP in the primary HSCs and primary hepatocytes isolated from the CCl 4 -treated mice and revealed that HOTTIP increased significantly in both primary HSCs and hepatocytes with the extension of CCl 4 inducing time (Fig. 1C) . Notably, it increased more significantly in the primary HSCs (Fig. 1C) . Therefore, the relative expressions of HOTTIP in the cultured primary HSCs isolated from healthy mice were also determined up to day 8, and results showed that HOTTIP expressions were significantly elevated in a timedependent manners (Fig. 1D) . Moreover, treatment with TGF-β1, a widely used stimulus for HSC activation, significantly upregulated the expression of HOTTIP and miR-148a in human LX-2 HSCs (Fig. 1E ). These results suggest that greater expression of HOTTIP was linked to the progression of liver fibrosis.
Downregulation of HOTTIP alleviated the CCl 4 -induced liver fibrosis in mice
To determine the role of the abnormal expression of HOTTIP in liver fibrosis, the CCl 4 -treated mice received the expressing sh-HOTTIP adenoviral vector Ad-shHOTTIP to reduce HOTTIP levels in vivo, and it effectively downregulated HOTTIP expression in the liver tissues of the CCl 4 -treated mice ( Fig. 2A) . Moreover, the high HYP content induced in liver tissues by CCl 4 was significantly decreased by Ad-shHOTTIP (Fig. 2B) . We also observed that the relative expression of HOTTIP was markedly reduced by Ad-shHOTTIP delivery in both the primary HSCs and primary hepatocytes of the CCl 4 -treated mice ( Figures 2C and 2D) . The mouse liver tissue samples were analyzed for mRNA and protein expressions of α-SMA and Col-1, which were the important factors in liver fibrosis, and the results showed that Ad- shHOTTIP effectively decreased α-SMA and Col-1 expression at both the mRNA and protein levels ( Figures 2E and 2F ). Taken together, this indicates that suppression of HOTTIP could alleviate CCl 4 -induced liver fibrosis in mice.
Downregulation of HOTTIP inhibited the viability and activation of HSCs in vitro
We further examined the effect of HOTTIP on the viability and activation of HSCs in vitro. As indicated in Fig. 3A , HOTTIP siRNA (si-HOTTIP) transfection significantly inhibited HOTTIP expression in the cultured HSCs. In addition, the relative viability of HSCs were significantly reduced after transfection of si-HOTTIP (Fig. 3B) . The decrease of HOTTIP expression downregulated both the mRNA and protein levels of α-SMA and Col-1 ( Figures  3C and 3D left) . In LX-2 cells, Western blotting demonstrated that decreased HOTTIP or decreased miR-148a reduced the protein levels of α-SMA and Col I that had been induced 
by TGF-β1 (Fig. 3D right) . The TGF-β/Smad signaling pathway was confirmed to be closely related to HSCs activation of liver fibrosis in vivo and in vitro. Thus we next explored the effect of HOTTIP silencing on the TGF-β/Smad signaling pathway in HSCs and found that HOTTIP silencing induced a significant decrease in the mRNA and protein expression of TGFBR1, TGFBR2, Smad2 and Smad3 in HSCs in vitro (Fig. 3E ). Taken together, these results suggest that HOTTIP silencing inhibits the activation of HSCs through the TGF-β/Smad signaling pathway. Given the possible interactions between HOTTIP and miR-148a, and based on bioinformatics analysis, we profiled miR-148a expression in HSCs after HOTTIP silencing. As expected, downregulation of HOTTIP promoted miR-148a expression in HSCs (Fig. 3F) . Moreover, miR-148a expression was significantly downregulated in the liver tissues of the CCl 4 -treated mice, while HOTTIP silencing by Ad-shHOTTIP significantly enhanced miR148a in the CCl 4 -treated mice (Fig. 3G) . It was also observed that miR-148a expression was inhibited by CCl 4 in the primary HSCs and hepatocytes, and HOTTIP silencing elevated miR148a expression (Fig. 3H) . The relative expressions of miR-148a in the primary HSCs isolated from the CCl 4 -treated mice were found to decrease in a time-dependent manner (Fig. 3I) . Similarly, miR-148a expressions were also gradually decreased in the cultured primary HSCs during culture days (Fig. 3J) . These data indicate that miR-148a was involved in liver fibrosis by affecting HSC activation.
miR-148a inhibited the activation of HSCs in vitro
Based on the above findings, we sought to investigate the precise role of miR-148a in HSC activation. The induction of miR-148a in HSCs significantly reduced the mRNA levels of α-SMA and Col-1 when compared with the untransfected HSCs (Fig. 4A) . Additionally, the protein expressions of α-SMA and Col-1 were also significantly decreased by miR-148a overexpression in both mouse and human HSCs (Fig. 3D and 4B ). On the other hand, the Figures 4C and 4D) . Overall, our results showed that, in contrast to HOTTIP, miR-148a had negative effects on HSC activation.
The down-regulated HOTTIP reduced TGFBR1/2 and Smad2/3 in HSCs through negative regulation of miR-148a
To test whether miR-148a mediated the effect of HOTTIP on HSCs activation, we first performed the Dual-Luciferase Reporter Assay to validate the direct binding between mouse HOTTIP and miR-148a based on the predicted HOTTIP binding site in miR-148a (Fig. 5A) . The HOTTIP luciferase reporter vectors containing the miR-148a binding site (pmirGLO-HOTTIP) or mutated site (pmirGLO-HOTTIP-MU) were constructed. The miR-148a levels negatively regulated the relative luciferase activity of pmirGLO-HOTTIP but had no obvious effect on pmirGLO-HOTTIP-MU luciferase activity in HEK293T cells, suggesting the interaction between HOTTIP and miR-148a in a sequence-specific manner (Fig. 5A) . Bioinformatics analysis and luciferase assays also supported the interaction between human HOTTIP and has-miR-148a (Fig. 5B) . Indeed, the relative expression of miR-148a was inhibited by HOTTIP, but it was elevated by HOTTIP knockdown in the primary HSCs (Fig. 5C ). To determine whether miR-148a was involved in regulation of the TGF-β/Smad signaling pathway due to effects from HOTTIP, we examined the effect of simultaneous downregulation of HOTTIP and miR-148a on the TGF-β/Smad signaling pathway. Notably, downregulated miR-148a markedly restored the mRNA and protein expression of TGFBR1, TGFBR2, Smad2, and Smad3 that had been decreased by HOTTIP silencing in both mouse and human HSCs ( Fig.  5D and 5E ). miR-148a knockdown also markedly restored the decreased mRNA and protein expression of α-SMA and Col-1 that had been caused by HOTTIP silencing in both mouse and human HSCs (Fig. 5E ). These data suggest that miR-148a mediated the inhibition of HOTTIP Cell Figures 6A and 6B) . Results from the Dual-Luciferase Reporter Assay supported our hypothesis, revealing that miR-148a expression negatively regulated the luciferase activity of the TGFBR1/TGFBR2 luciferase reporter vectors containing the miR-148a binding site but had no obvious effect on the luciferase activity of luciferase reporter vectors containing a mutated site in HEK293T cells ( Figures  6A and 6B) . Moreover, the human TGFBR1 and TGFBR2 3′UTR sequences were found to contain target sites for miR-148a (Fig. 6C) . Luciferase assays validated that TGFBR1 and TGFBR2 were the targets of hsa-miR-148a (Fig. 6C) . Further studies showed that the forced miR-148a significantly inhibited the mRNA and protein expressions of TGFBR1 and TGFBR2 in primary HSCs as compared with the control (Fig. 6D) , and downregulation of miR-148a in HSCs had the opposite effect on TGFBR1 and TGFBR2 expression (Fig. 6E) . Thus, we confirmed that both TGFBR1 and TGFBR2 were the targets of miR-148a.
Down-regulation of HOTTIP inhibited the activation of HSCs in vitro via negative regulation of miR-148a
We next focused on whether HOTTIP inhibited the activation of HSCs by regulating miR148a. We observed that the miR-148a knockdown markedly restored the decreased mRNA and protein expression of α-SMA and Col-1 that had been caused by HOTTIP silencing in both mouse and human HSCs ( Figures 5E, 7A and 7B ). These results corroborated that HOTTIP contributed to HSC activation, at least in part, through negative regulation of miR-148a. 
Discussion
Liver fibrosis is a pathological change caused by chronic liver damage and is characterized by impaired liver function and an excessive hepatic deposition of ECM in the Disse space of the sinusoidal cell layer [21] . Without an effective control, liver fibrosis further develops into irreversible end-stage liver cirrhosis or even liver cancer, with high mortality. HSC activation is the fundamental process in liver fibrosis resulting from different causes and impact factors [22] . In one study, in response to acute or chronic liver injury, normal resting HSCs were transformed into activated HSCs that synthesized and secreted collagen-rich ECM [23] . Targeting the regulatory mechanism of HSC activation may serve as an effective therapeutic strategy for liver fibrosis.
HOTTIP, located on 7p15.2, plays a pivotal role in a number of human cancers, including gastric cancer, hepatocellular carcinoma, and colorectal cancer [14] [15] [16] . High HOTTIP expression has been detected in human HCC specimens and associated with the clinical progression and disease outcome of HCC patients [15] . More importantly, HOTTIP has been demonstrated to dysregulate in early stage of human HCC formation [24] . In the current study, we showed that HOTTIP was up-regulated during the progression of liver fibrosis and that downregulation of HOTTIP significantly alleviated the CCl 4 -induced liver fibrosis in mice, a well-established model for liver fibrosis. Moreover, we also identified HOTTIP as a potent inducer of HSC activation. Studies on the role of HOTTIP in human diseases have mainly focused on its oncogenic activity, which fuels tumor cell growth, metabolism, and metastasis. HOTTIP expression has been observed to elevate in developing hind limbs, and it is implicated in bat wing development [25] . HOTTIP has also been shown to be significantly upregulated in the chondrocytes of osteoarthritis, and it has been demonstrated to regulate cartilage integrity [26] . The present study is the first to evaluate the role of HOTTIP in liver fibrosis and confirmed that HOTTIP dysregulation is associates with in vivo HSC activation.
MiR-148a, as a liver-related miRNA, has been implicated in HCC initiation, progression and liver fibrosis. MiR-148a was previously reported to induce hepatocytic differentiation, thereby inhibiting the formation and development of HCC; remarkably, miR-148a mimetic treatment may significantly reduce liver fibrosis of developed tumors in mice [11] . Recombinant human TGFβ1, a widely used stimulus for HSC activation, has significantly increased the expression level of miR-148a in human HSC, while transfection of miR-148a inhibitor evidently reduced COL6A1 levels associated with HSC activation [27] . A recent study established a link between miR-148a and the Wnt/β-catenin pathway [28] . The Wnt/ β-catenin pathway has been shown to play essential roles in HSC activation and to eventually promote the progression of liver fibrosis [29] . Obviously, these prior studies indicate that miR-148a could be an important determinant in liver fibrosis. In the present study, we showed that miR-148a overexpression inhibited the activation of HSCs in vitro, and we further showed the functional involvement of miR-148a in the development of liver fibrosis induced by HOTTIP. We identified that HOTTIP negatively regulated miR-148a in HSCs, and the new targets of miR-148a, TGFBR1, and TGFBR2 were significantly increased, thereby enhancing HSC activation. TGF-β/Smad signaling, tightly regulated by TGFBR1/TGFBR2 complexes, was the essential inducer for HSC activation and survival in liver fibrosis [30, 31] .
HOTTIP was located at chr. 7p15.2 (27200421..27207259) and chr. 6B3 (52262775..52267603) in the human and mouse genomes, respectively, while miR148a was located in human chr. 7p15.2 (25949919..25949986) and mouse chr. 6B3 (51269812..51269910), respectively. The interaction of HOTTIP/WDR5 (MLL) generates a transcription loop involving the activation of nearby genes at the 5' end of the locus HOXA (HOXA13-HOXA9) . Importantly, the transcription loop is located about 300bp upstream of the HOXA (HOXA13-HOXA9) 5' end and the miR-148a gene is not in this transcription loop. The chromosome location and sequence similarity suggest that some lncRNAs might serve as the host genes of miRNA and act in close association with miRNAs expression and function. However, in the present study, we observed that HOTTIP negatively regulated miR148a in a sequence-specific manner. 
Conclusion
Our study confirmed that HOTTIP is involved in the progression of liver fibrosis by promoting HSC activation and miR-148a downregulated by HOTTIP played a central role in this pathogenic process. Notably, TGFBR1 and TGFBR2 were identified as the new targets of miR-148a in HSCs. The high level of HOTTIP downregulated miR-148a, increased the levels of TGFBR1 and TGFBR2 and thus contributed to liver fibrosis (Fig. 8) . Finally, our study further illustrated the underlying mechanisms for liver fibrosis and is expected to provide new insights into therapeutic strategy. 
